Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

generics (uk) limited - levodopa ; carbidopa ; entacapone - film coated tablet - 100/25/200 milligram - levodopa, decarboxylase inhibitor and comt inhibitor

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

generics (uk) limited - levodopa ; carbidopa ; entacapone - film coated tablet - 125/31.25/200 milligram - levodopa, decarboxylase inhibitor and comt inhibitor

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

generics (uk) limited - levodopa ; carbidopa ; entacapone - film coated tablet - 150/37.5/200 milligram - levodopa, decarboxylase inhibitor and comt inhibitor

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

generics (uk) limited - levodopa ; carbidopa ; entacapone - film coated tablet - 175/43.75/200 milligram - levodopa, decarboxylase inhibitor and comt inhibitor

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

generics (uk) limited - levodopa ; carbidopa ; entacapone - film coated tablet - 200/50/200 milligram - levodopa, decarboxylase inhibitor and comt inhibitor

Malta - Kiingereza - Medicines Authority

fair-med healthcare gmbh planckstr. 13, 22765 hamburg, germany - levodopa, carbidopa - tablet - levodopa 27 mg carbidopa 250 mg - anti-parkinson drugs

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

fairmed healthcare gmbh - levodopa; carbidopa - tablet - 12.5/50 milligram(s) - dopa and dopa derivatives; levodopa and decarboxylase inhibitor

Marekani - Kiingereza - NLM (National Library of Medicine)

abbvie inc. - levodopa (unii: 46627o600j) (levodopa - unii:46627o600j), carbidopa (unii: mnx7r8c5vo) (carbidopa anhydrous - unii:kr87b45rgh) - levodopa 20 mg in 1 ml - duopa® is indicated for the treatment of motor fluctuations in patients with advanced parkinson’s disease. duopa is contraindicated in patients who are currently taking a nonselective monoamine oxidase (mao) inhibitor (e.g., phenelzine and tranylcypromine) or have recently (within 2 weeks) taken a nonselective mao inhibitor. hypertension can occur if these drugs are used concurrently [see drug interactions ( 7.1 and 7.2 )] . risk summary there are no adequate data on the developmental risk associated with the use of duopa in pregnant women. in animal studies, carbidopa-levodopa has been shown to be developmentally toxic (including teratogenic effects) at clinically relevant doses (see data) . the estimated background risk of major birth defects and miscarriage in the indicated population is unknown. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. data animal data when administ

Marekani - Kiingereza - NLM (National Library of Medicine)

wockhardt usa llc. - levodopa (unii: 46627o600j) (levodopa - unii:46627o600j), entacapone (unii: 4975g9nm6t) (entacapone - unii:4975g9nm6t), carbidopa (unii: mnx7r8c5vo) (carbidopa anhydrous - unii:kr87b45rgh) - levodopa 50 mg - carbidopa, levodopa and entacapone tablets, a combination drug consisting of levodopa, carbidopa (dopa decarboxylase inhibitor), and entacapone (catechol-o-methyltransferase-comt inhibitor) is indicated for the treatment of parkinson's disease. carbidopa, levodopa and entacapone tablets can be used: - to substitute (with equivalent strengths of each of the three components) carbidopa/levodopa and entacapone previously administered as individual products. - to replace carbidopa/levodopa therapy (without entacapone) when patients experience the signs and symptoms of end-of-dose "wearing-off" and when they have been taking a total daily dose of levodopa of 600 mg or less and have not been experiencing dyskinesias. carbidopa, levodopa and entacapone tablets are contraindicated in patients: - taking nonselective monoamine oxidase (mao) inhibitors (e.g., phenelzine and tranylcypromine). these nonselective mao inhibitors must be discontinued at least two weeks prior to in

Umoja wa Ulaya - Kiingereza - EMA (European Medicines Agency)

orion corporation - levodopa, carbidopa, entacapone - parkinson disease - anti-parkinson drugs - corbilta is indicated for the treatment of adult patients with parkinson’s disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (ddc) inhibitor treatment.